# US 2014/0154226 A1 · Regeneration and repair of neural tissue using postpartum-derived cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154226 A1
- Document ID: US20140154226A1
- Status: Published application
- Kind: A1
- Application number: 14/152,649
- Filed: 2014-01-10
- Published: 2014-06-05
- Earliest claimed: 2003-06-27
- Assignees: DePuy Synthes Products, Inc.
- Applicants: DePuy Synthes Products, LLC
- Inventors: Darin J. Messina; Alexander M. Harmon; Ian R. Harris; Anthony J. Kihm; Sanjay Mistry; Agnieszka Seyda; Chin-Feng Yi; Anna Gosiewska
- Web page: https://patentgrep.com/patent/US20140154226A1

## CPC

- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61L 27/3834: {Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells}
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61L 2300/412: Tissue-regenerating or healing or proliferative agents
- A61L 2300/414: Growth factors
- A61L 2300/64: Animal cells
- A61L 2430/32: for nerve reconstruction
- C12N 2500/32: Amino acids
- C12N 2500/34: Sugars
- C12N 2500/44: Thiols, e.g. mercaptoethanol
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2500/95: Protein-free medium and culture conditions
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/21: Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- C12N 2501/23: Interleukins [IL]
- C12N 2502/02: embryonic cells
- C12N 2506/02: from embryonic cells
- C12N 2506/03: from non-embryonic pluripotent stem cells
- C12N 2509/00: Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N 2533/50: Proteins
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of neural tissue using the postpartum-derived cells are also disclosed.

## Claims

### Claim 1

A method of treating a patient having a neurodegenerative condition, the method comprising administering to the patient one or more cells in an amount effective to treat the neurodegenerative condition, wherein said cells are isolated from human umbilical cord tissue substantially free of blood, or are generated from cultures of said isolated cells, wherein said cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype; wherein said cells can grow in at least about 5% oxygen; wherein said cells exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and wherein said cells lack production of CD 117.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cells produce each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A, B, C.

### Claim 3 (depends on 1)

The method of claim 1, wherein said cells lack the production of CD31, CD34, CD45, CD80, CD86, CD141, CD178, B7-H2, HLA-G and HLA-DR, DP, DQ.

### Claim 4 (depends on 1)

The method of claim 1, wherein said cells secrete each of the factors MCP-1, IL-6, IL-8, GCP-2, HGF, KGF, FGF, HB-EGF, BDNF, TPO and TIMP1.

### Claim 5 (depends on 1)

The method of claim 1, wherein said cells do not secrete one or more of the factors SDF-1 alpha, TGF-beta2, ANG2, PDGFbb and VEGF.

### Claim 6 (depends on 1)

The method of claim 1, wherein said cells exhibit:
a) increased expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, of at least one of a gene encoding: interleukin 8; reticulon 1; chemokine (C-X-C motif) ligand 1 (melonoma growth stimulating activity, alpha); chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2); chemokine (C-X-C motif) ligand 3; and tumor necrosis factor, alpha-induced protein 3; and
b) reduced expression, relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell, of at least one of a gene encoding: short stature homeobox 2; heat shock 27 kDa protein 2; chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1); elastin (supravalvular aortic stenosis, Williams-Beuren syndrome); Homo sapiens mRNA; cDNA DKFZp586M2022 (from clone DKFZp586M2022); mesenchyme homeo box 2 (growth arrest-specific homeo box); sine oculis homeobox homolog 1 (Drosophila); crystallin, alpha B; disheveled associated activator of morphogenesis 2; DKFZP586B2420 protein; similar to neuralin 1; tetranectin (plasminogen binding protein); src homology three (SH3) and cysteine rich domain; cholesterol 25-hydroxylase; runt-related transcription factor 3; interleukin 11 receptor, alpha; procollagen C-endopeptidase enhancer; frizzled homolog 7 (Drosophila); hypothetical gene BC008967; collagen, type VIII, alpha 1; tenascin C (hexabrachion); iroquois homeobox protein 5; hephaestin; integrin, beta 8; synaptic vesicle glycoprotein 2; neuroblastoma, suppression of tumorigenicity 1; insulin-like growth factor binding protein 2, 36 kDa; Homo sapiens cDNA FLJ12280 fis, clone MAMMA1001744; cytokine receptor-like factor 1; potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4; integrin, beta 7; transcriptional co-activator with PDZ-binding motif (TAZ); sine oculis homeobox homolog 2 (Drosophila); KIAA1034 protein; vesicle-associated membrane protein 5 (myobrevin); EGF-containing fibulin-like extracellular matrix protein 1; early growth response 3; distal-less homeo box 5; hypothetical protein FLJ20373; aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid dehydrogenase, type II); biglycan; transcriptional co-activator with PDZ-binding motif (TAZ); fibronectin 1; proenkephalin; integrin, beta-like 1 (with EGF-like repeat domains); Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 1968422; EphA3; KIAA0367 protein; natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C); hypothetical protein FLJ14054; Homo sapiens mRNA; cDNA DKFZp564B222 (from clone DKFZp564B222); BCL2/adenovirus E1B 19 kDa interacting protein 3-like; AE binding protein 1; cytochrome c oxidase subunit VIIa polypeptide 1 (muscle); similar to neuralin 1; B cell translocation gene 1; hypothetical protein FLJ23191; and DKFZp586L151.

### Claim 7 (depends on 1)

The method of claim 1, wherein the neurodegenerative condition is a chronic or progressive neurodegenerative condition.

### Claim 8 (depends on 7)

The method of claim 7, wherein the chronic or progressive neurodegenerative condition is Huntington's disease, amyotrophic lateral sclerosis, tumor, multiple sclerosis or chronic peripheral nerve injury.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cells are induced in vitro to differentiate into a neural lineage cells prior to administration.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cells are genetically engineered to produce a gene product that promotes treatment of the neurodegenerative condition.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cells are administered by injection or infusion.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cells are administered by implantation of a matrix or scaffold containing the cells.

### Claim 13

A pharmaceutical composition for treating a patient having a neurodegenerative condition, comprising a pharmaceutically acceptable carrier and one or more cells in an amount effective to treat the neurodegenerative condition, wherein said cells are isolated from human umbilical cord tissue substantially free of blood, or are generated by culturing said isolated cells, wherein said cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype; wherein said cells can grow in at least about 5% oxygen; wherein said cells exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and wherein said cells lack production of CD117.

### Claim 14 (depends on 13)

The pharmaceutical composition of claim 13 wherein said cells produce each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A, B, C.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14 wherein said cells lack the production of each of CD31, CD34, CD45, CD80, CD86, CD141, CD178, B7-H2, HLA-G, and HLA-DR, DP, DQ.

### Claim 16 (depends on 13)

The pharmaceutical composition of claim 13, wherein the cells are induced in vitro to differentiate into a neural lineage cells prior to formulation of the composition.

### Claim 17 (depends on 13)

The pharmaceutical composition of claim 13, wherein the cells are genetically engineered to produce a gene product that promotes treatment of the neurodegenerative condition.

### Claim 18 (depends on 13)

The pharmaceutical composition of claim 13, comprising at least one other agent selected from the group consisting of an anti-inflammatory agent, and anti-apoptotic agent, an antioxidant and a growth factor.

### Claim 19 (depends on 13)

A kit for treating a patient having a neurodegenerative condition, the kit comprising the pharmaceutical composition of claim 13 and instructions for using the kit in a method of treating the patient.

### Claim 20

A method of treating a patient having a neurodegenerative condition, the method comprising administering to the patient, in an amount effective to treat the neurodegenerative condition, a composition comprising an extracellular matrix, conditioned medium or cell lysate of cells isolated from human umbilical cord tissue substantially free of blood, or generated by culturing said isolated cells, wherein said cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype; wherein said cells can grow in at least about 5% oxygen; wherein said cells exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and wherein said cells lack production of CD117.

### Claim 21

A pharmaceutical composition for treating a patient having a neurodegenerative condition, which comprises a pharmaceutically acceptable carrier and a component selected from a conditioned medium, extracellular matrix or cell lysate of cells isolated from human umbilical cord tissue substantially free of blood, or generated by culturing said isolated cells, wherein said cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype; wherein said cells can grow in at least about 5% oxygen; wherein said cells exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and wherein said cells lack production of CD117.

### Claim 22 (depends on 21)

A kit for treating a patient having a neurodegenerative condition, which comprises the pharmaceutical composition of claim 21; and instructions for using the kit components for treatment of the neurodegenerative condition.
